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Abstract
This is the first report of the direct identification of a HLA-DRB1*03 measles-derived peptide from measles virus infected EBV-
transformed B cells. We purified HLA-DR3-peptide complexes from EBV-B cells infected with measles virus (Edmonston strain) and
sequenced the HLA-DR3-peptides by mass spectrometry. A class II peptide, derived from a measles phosphoprotein, ASDVETAE-
GGEIHELLRLQ (P1, residues 179–197), exhibited the capacity to stimulate peripheral blood mononuclear cells to proliferate. Our data
provides direct evidence that the antigenic peptide of measles virus was processed by antigen-presenting cells, presented in the context of
HLA class II molecules, and was recognized by peripheral blood T cells from healthy individuals previously immunized with measles
vaccine. The approach described herein provides a useful methodology for the future identification of HLA-presented pathogen-derived
epitopes using mass spectrometry. The study of cell-mediated immune responses to the measles-derived peptide in immune persons should
provide significant insight into the design and development of new vaccines.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
The World Health Organization has targeted measles for
worldwide eradication, requiring an immunogenic vaccine
for the genetically heterogeneous outbred population. Al-
though well controlled by vaccination programs in indus-
trialized countries, measles virus (MV) infection continues
to be one of the major causes of childhood morbidity and
mortality in developing countries (Gellin and Katz, 1994).
The requirement for a cold chain (storage), the induction of
low seroconversion rates in the presence of maternal anti-
bodies, the vaccine failure rate, and the inability to use the
vaccine in some immunocompromised conditions are the
major drawbacks of the live-attenuated measles vaccine (El
Kasmi et al., 2000; Albrecht et al., 1977). The limitations of
the live vaccine combined with inadequate coverage in
developing countries leads to approximately one million
measles-related deaths annually (Jaye et al., 1998; Sabin,
1991). Thus, there is a need to develop alternative vaccines
that are thermostable, safe, and designed to avoid recogni-
tion and neutralization by passive maternal antibodies (El
Kasmi et al., 1999; Jaye et al., 1998). Such vaccines should
induce long-lasting cell-mediated and humoral immune re-
sponses. For this reason, the development of a candidate
peptide-based vaccine, based on immunologically relevant
information on naturally processed and presented measles
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virus-derived peptides eluted from HLA class I and class II
molecules, would have a significant impact.
Defining peptide epitopes recognized by CD8 and
CD4 T lymphocytes involved in immune responses has
generated tremendous interest (Germain, 1994a). We previ-
ously demonstrated that humoral immune responses to mea-
sles-encoded proteins are strongly associated with the hu-
man leukocyte antigen (HLA) class I and class II genes
(Poland et al., 1999). In particular, HLA-DRB1*03 (DR3)
alleles are significantly associated with measles vaccine
seronegativity and play an important role in the immune
response to MV (Poland et al., 2001a). Identification and
comparison of the repertoire of measles-derived peptides
that bind to class II HLA-DR3 molecules in poor and high
responders to measles vaccine is important for designing
effective vaccines against measles. The HLA class I and
class II antigen-processing pathways play a critical role in
the activation of measles-specific T lymphocytes by pre-
senting peptide epitopes derived from viral proteins (Pamer,
1999). The HLA class II molecules bind and present exog-
enous measles antigens for recognition by CD4 helper T
cells and play an important role in the immune response to
measles (Germain, 1994b, 1995; Pamer, 1999). Alterna-
tively, class II molecules can also use the endogenous path-
way of measles virus antigen presentation (Nuchtern et al.,
1990; Sekaly et al., 1988). Identification of such immuno-
genic measles epitopes, which are recognized by T and B
lymphocytes, would advance peptide-based therapies and
vaccine development (Poland et al., 2001b). However, a
potential obstacle to the development of a peptide-based
measles vaccine is the high degree of human HLA gene
polymorphism (Doolan et al., 2000).
HLA molecules bind antigenic peptides and display them
to T cell receptors on the surface of helper T cells (Garcia
et al., 1999; Brown et al., 1988; Stern et al., 1994). Adoptive
immune responses are therefore limited by the spectrum of
immunogenic peptides displayed to T cells. Limitations in
identifying class II peptides include the difficulty in detect-
ing pathogen-derived peptides eluted from HLA class II–
peptide complexes and the lack of knowledge regarding
HLA class II presentation of measles virus peptides, as only
a few human measles virus class I peptides and HLA class
II restricted cytotoxic T lymphocytes (CTL) responses are
described in the literature (Herberts et al., 2001; van Els et
al., 2000; van Binnendijk et al., 1993; Jacobson et al., 1989).
However, the rapid characterization of defined peptides that
are critical to viral immunity, including measles, has been
significantly enhanced by mass spectrometry (MS), which
provides peptide sequence information at the femtomole
level of sensitivity.
Although direct sequencing of naturally processed pep-
tides bound to HLA class I and II molecules by liquid
chromatography mass spectrometry (LC-MS) is well-estab-
lished (Dongre et al., 2001; de Jong, 1998), identification of
pathogen-derived peptides presents a formidable challenge
due to the diverse range of low-abundance peptides pre-
sented by HLA molecules. Strategies to reduce the com-
plexity of the mixture prior to introduction into the mass
spectrometer have often relied on multiple steps of re-
versed-phase (RP) liquid chromatography. However, this
approach does not effectively increase the peak capacity
because the separation mechanisms of each RP chromatog-
raphy step are not orthogonal.
We have adopted an approach, developed in the field of
proteomics, to resolve the profound biological complexity
presented in these investigations. The approach is based on
two truly orthogonal separation techniques, namely, (1)
strong cation exchange (SCX) chromatography, which sep-
arates peptides based on their charge; and (2) nano-RP
high-performance liquid chromatography, which uses hy-
drophobicity (Link et al., 1999; Washburn et al., 2001). This
fully automated, multidimensional chromatography-MS ap-
proach affords a geometric increase in the overall peak
capacity that dramatically increases the effective dynamic
range and the number of peptides that can be dissociated
(sequenced using data-dependent tandem-MS) for any given
sample.
An overview of the methodology we developed for iden-
tifying MHC class II peptides originating from measles
virus is shown in Fig. 1. This methodology provides a
powerful tool for the identification of pathogen-derived
HLA class II peptides that in turn can be evaluated as
potential subunit vaccine candidates. We report here for the
first time that naturally processed measles phosphoprotein
(P)-derived peptide was isolated and sequenced from class
II HLA-DR3 molecules of measles virus infected EBV-
transformed B (EBV-B) cell lines by mass spectrometry.
Results
Identification of the measles-specific HLA-DR3 peptides
by 2D nLC tandem-MS
An aliquot representing 25% of the peptide extract from
measles virus infected cells was subjected to two-dimen-
sional nLC, data-dependent tandem-MS and acquired a total
of 1371 tandem mass spectra from 10 SCX fractions. Pep-
tide sequences were identified by searching the spectra
against a subset of the NR database from NCBI using
SEQUEST software (Eng et al., 1994). Search results were
initially filtered on the basis of their cross-correlation score
(XCorr  2). From the 1371 tandem mass spectra acquired,
276 spectra met the search criteria, of which only one
spectrum returned a search result for a measles virus pep-
tide. The tandem mass spectrum of a triply charged precur-
sor with a m/z  689.69 ([M  H]  2067.05), eluting
in the 40 mM KCl SCX fraction, returned a SEQUEST
search result where the two top-ranked sequences were
peptides from multiple database entries for phosphoproteins
from the measles virus (Fig. 2A). The two candidate se-
quences, ASDVETAEGGEIHELLRLQ (designated MV-
496 I.G. Ovsyannikova et al. / Virology 312 (2003) 495–506
Fig. 1. Overview of the analytical method for isolating and sequencing MHC class II peptides. B cells infected with measles virus are lysed and MHC
molecule/peptide complexes are isolated on an antibody column. Dissociated peptides were loaded onto an automated 2D-LC-MS system. Peptides were
eluted from the SCX column by salt steps introduced by the autosampler. Data-dependent MS/MS experiments were conducted during the subsequent
reversed-phase nano-LC separations.
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P1) and ASDVETAEGGEIHKLLRLQ (designated MV-
P2), differ only by one amino acid, a Glu (E) versus Lys (K)
at position 192.
Although the search statistics did not conclusively rule
out the MV-P2 sequence, the difference between the two
candidate sequences, MV-P1 and MV-P2, is a nonconser-
vative amino acid change that can readily be distinguished
solely by molecular weight as the peptide ion mass differs
by 1 Da. The experimental monoisotopic mass for the nat-
urally processed peptide was [M  H]  2067.05, while
the theoretical values for MV-P1 and MV-P2 are 2067.03
and 2066.09, respectively, clearly in agreement with
MV-P1 (10 ppm mass error vs nearly 500 ppm for MV-
P2). Several of the expected product ions from synthetic
MV-P2 are also one mass unit lower than the observed
product ions in the naturally processed spectrum (data not
shown).
The tandem mass spectra of synthetic MV-P1 (Fig. 2B)
relative to the naturally processed peptide (Fig. 2A) are
quite similar. Although product ions in the tandem mass
Fig. 2. Tandem mass spectra of m/z  689.7 obtained from the 40 mM SCX fraction with their corresponding SEQUEST scores. (A) Naturally processed
peptide (inset shows an expansion of the m/z range 720 to 920). (B) Synthetic peptide ASDVETAEGGEIHELLRLQ (inset shows an expansion of the m/z
range 720 to 920).
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spectrum from the naturally processed peptide (Fig. 2A) are
only marginally more intense than noise, a series of doubly
charged y product ions ranging from y11 to y16, as well as the
singly charged b2, b3, and a4 product ions, are observed for
both the naturally processed and the synthetic peptides,
which resulted in significant cross-correlation (Xcorr) and
Cn scores (Figs. 2A and B) (Smith et al., 2002; Eng et al.,
1994).
To be prudent, we carried out additional measurements
to ensure confident identification of the naturally processed
MHC class II peptide. First, we used the synthetic peptide to
optimize the collision energy for the tandem MS experi-
ments (optimized collision voltage of 24 V shown in Figs.
3A and B vs 26.8 V for the data shown in Figs. 2A and B).
Second, we adopted a more focused data-dependent analy-
sis where m/z  698.7 was selected as a priority precursor
Fig. 3. Tandem mass spectra of m/z 689.7 from (A) naturally processed peptide with targeted data-dependent analysis and increased loading as compared to
the data shown in Fig. 2a (inset shows the selected ion current for m/z  689.67  0.5 over a 15-min RP retention time window); (B) naturally processed
peptide spiked with 500 fmol of the synthetic peptide (inset shows the selected ion current for m/z 689.67 0.5 over a 15-min RP retention time window).
The peak tailing in Fig. 3b clearly indicates we have overloaded the column in the standard additions experiment; however, the retention times in Figs. 3A
and B are still within 5% of each other.
499I.G. Ovsyannikova et al. / Virology 312 (2003) 495–506
ion and the survey scan was restricted to m/z  650 to 720.
Although this strategy does not enhance the minimum level
of detection, it acts as an additional dimension of separation
in the gas phase that focuses data-dependent acquisition on
fewer potential precursor peptides at the expense of having
to carry out multiple runs (Spahr et al., 2002). Third, we
used an aliquot representing 50% of the total extract in an
attempt to improve the signal-to-noise ratio of the product–
ion spectrum. Fourth, we designed a standard addition ex-
periment to determine if the synthetic peptide coeluted in
the same SCX fraction and subsequently had the same RP
retention time as the naturally processed sample (i.e., an
increase in the signal-to-noise for the spiked sample).
We analyzed an aliquot representing 50% of the total
extract by two-dimensional nLC tandem-MS after replacing
the SCX, C8, and C18 columns with new columns that had
not seen any synthetic MV-P1 peptide or naturally pro-
cessed peptide extracts. These experiments again yielded a
tandem mass spectrum for m/z 689.65 (Fig. 3A) eluting in
the 40 mM KCl fraction. A small amount of this m/z was
also detected, at the same reversed-phase retention time, in
the 60 mM KCl fraction. For the standard addition experi-
ment, 500 fmol of synthetic MV-P1 was spiked, prior to the
initial desalting step described under Materials and meth-
ods, into the remaining aliquot of peptide extract represent-
ing 17% of the total. Synthetic MV-P1 eluted predomi-
nantly in the 40 mM SCX fraction (65% of total response)
with 21% of the total response being detected in the 20 mM
KCl fraction and 14% in the 60 mM KCl fraction. The
tandem mass spectrum of the coeluting synthetic MV-P1
and naturally processed MV-P1 from the 40 mM KCl frac-
tion is shown in Fig. 3B. Clearly, the synthetic peptide
behaves identically to the naturally processed peptide iden-
tified in earlier experiments (Fig. 2A). Thus, we conclude
that we have identified the naturally processed peptide as
being ASDVETAEGGEIHELLRLQ (MV-P1) from the
measles virus phosphoprotein.
Finally, by comparing the relative responses from the
standard addition experiment (Fig. 3B) to the naturally
processed sample (Fig. 3A), we estimate that the tandem
MS spectrum represents approximately 20 fmol of the nat-
urally processed peptide (Fig. 3A). Relative to responses
observed for other peptides from endogenous proteins, the
MV-P1 peptide is a minor epitope, where the more abundant
endogenous peptides were observed with 100-fold higher
MS responses than observed for MV-P1.
Proliferative response of vaccinated donors to measles P1
and P2 peptides
We examined recognition of these measles-derived pep-
tides by peripheral blood T cells from 95 healthy subjects
previously immunized with measles-mumps-rubella-II
(MMR-II) vaccine as a means of determining the immuno-
logic relevance of this peptide. PBMC from vaccinated
subjects were responsive to synthetic P1 and P2 peptides in
vitro. The results revealed large interindividual variation
among 95 tested subjects, but we observed little variability
between experiments on the same subject. Fig. 4 shows the
distribution of counts per minute (cpm) in lymphoprolifera-
tive assays. Using a cutoff value for significant lymphopro-
liferative responses (SI  3), the stimulatory responses
could be grouped into the following patterns of response.
The median cpm value was lower for unstimulated cells
(cpm  274) than for MV vaccine (cpm  1277, P 
Fig. 4. Box plots of counts per minute (cpm) by lymphoproliferative responses. Values are presented on a log scale. Top and bottom of boxes represent the
third and first quartiles, respectively. Middle line represents median, plus sign represents mean, and vertical lines represent values falling within 1.5 times
the interquartile range to either side of the first and third quartile. Circles represent outliers falling outside of the vertical lines.
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0.001), measles-derived P1 (cpm 472, P 0.001), and P2
(cpm  359, P  0.001) stimulated cells.
Measles virus stimulation indices (median 4.1, range
0.5–29.1) were generally higher than measles P1 peptide
(median 1.4, range 0.5–20.3) or P2 peptide stimulation
indices (median 1.2, range 0.5–16.2). Figs. 5 and 6 indicate
modest but positive correlations of MV-stimulated lympho-
proliferative responses (SI) with P1 and P2 SIs (Spearman
correlation coefficients  0.38 and 0.21, respectively)
across all subjects. Sixty of the 95 subjects (63%) had MV
stimulation indices greater than 3.0, indicating that measles
vaccine virus contains multiple T cell epitopes. Compara-
tively, measles-derived P1 and P2 peptides were recognized
in 17 and 5% of the subjects, respectively, thereby suggest-
ing a higher frequency of P1-specific T cells in subjects
after measles immunization. Among the 60 subjects who
responded to the MV, 12 also responded to the P1 peptide
(sensitivity  20%) and three responded to the P2 peptide
(sensitivity  5%). We saw little or no proliferation in
healthy subjects who were immunized with MMR-II vac-
Fig. 5. Plot of MV stimulation indices with measles P1 peptide stimulation indices. Values are graphed on a log scale. Dashed lines indicate proliferative
responsiveness cut point of 3.0. Spearman rank correlation coefficient is 0.38 (P  0.001), sensitivity  0.20, specificity  0.89.
Fig. 6. Plot of MV stimulation indices with measles P2 peptide stimulation indices. Values are graphed on a log scale. Dashed lines indicate proliferative
responsiveness cut point of 3.0. Spearman rank correlation coefficient is 0.21 (P  0.04), sensitivity  0.05, specificity  0.94.
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cine to randomly chosen measles fusion (F) peptide from
the MV proteome (data not shown). Thus, the lymphopro-
liferative response of the vaccinated subjects to measles
naturally processed P1 peptide may be of further interest in
studies to investigate induction of protective immunity to
measles.
Discussion
The identification and characterization of antigenic
epitopes of infectious pathogens by CD4 T cells is of
major interest (Peakman et al., 1999; Germain, 1994a; Ger-
main and Hendrix, 1991). In our study, we identified a HLA
class II naturally processed peptide derived from MV phos-
phoprotein. The amino acid sequence of P1 peptide (ASD-
VETAEGGEIHELLRLQ) obtained from direct sequencing
by nLC/MS/MS was concordant with the measles viral
genome.
Measles is a negative-strand RNA virus. Measles virus P
gene of Paramyxoviruses encodes three proteins: P
polypeptide and two nonstructural gene products, C and V
polypeptides, which encode virulence functions in vivo
(Patterson et al., 2000). The P gene encodes a heavily
phosphorylated protein (60 kDa), which, in association with
the polymerase (L) protein, is required for transcription and
replication of the ribonucleoprotein complex (Griffin and
Bellini, 1996). In addition, P protein also acts as a chaper-
one that interacts with and regulates the cellular localization
of nucleocapsid (N) protein and may assist in N assembly
(Griffin and Bellini, 1996; Horikami and Moyer, 1995).
Animals challenged with recombinant virus expressing the
H, N, or F measles structural protein were protected against
measles encephalitis, whereas matrix (M) or P protein im-
munization provided only partial protection (Brinckmann et
al., 1991).
The significance of our results resides in a technique
capable of identifying naturally processed pathogen-derived
peptides eluted from the open peptide binding groove of
class II HLA-DR molecules and the potential use of this
technique in directed vaccine development. Furthermore,
we have established the immunologic relevance of these
peptides by demonstrating their ability to induce recall im-
munity to measles in a lymphoproliferation assay among
HLA discordant subjects. Previous investigations of in vitro
PBMC proliferative responses to overlapping measles pep-
tides were difficult, and often a short-term preculture with
MV antigen and/or development of MV-specific T cell lines
and T cell clones were needed to visualize significant pro-
liferative response (Marttila et al., 1999). We detected re-
sponses to a single P1 epitope, representing residues 179–
197, in 17% of subjects without prior amplification of
specific cells among HLA discordant subjects. The measles-
derived P1 peptide is antigenic, as assessed by its capacity
to be recognized by PBMC isolated from subjects previ-
ously immunized with measles vaccine. Since we obtained
PBMC from subjects with unknown HLA types (i.e., many
were unlikely to be DR3 positive), it is likely that the
number of true peptide responders is underestimated. We
might, in fact, expect a low lymphoproliferative response
among DR3 subjects, as the stimulating peptide is a “non-
responder” peptide derived from DR3-positive subject.
These data provide direct evidence that MV antigenic pep-
tides were processed and could bind to HLA class II mol-
ecules. This information can only be obtained by direct
elution from class II HLA molecules isolated from APC.
Isolation and identification of naturally processed and
presented peptides greatly accelerates our ability to under-
stand mechanisms of immunogenicity and further illustrates
the importance of immunogenetics. It is conceivable that
vaccine nonresponders present a different spectrum of pep-
tides to the immune system compared to vaccine respond-
ers. If so, the importance of HLA restriction in the immune
response becomes primary in designing strategies to induce
protective immune responses. Such an understanding also
suggests an important approach to the directed design of
new vaccines. It may be possible to design a vaccine that is
a “cocktail” of peptides that induces protective immune
responses across the spectrum of a population’s HLA vari-
ability. The current limitation to this approach is the empiric
and inefficient process of identifying which peptides are
important in inducing a protective immunity and how they
are HLA-restricted, and demonstrating the immunologic
relevance of such peptides. Importantly, our results suggest
an important advance, as our process could be applied to
directed development of vaccines for any disease process
where stimulating antigens can be identified. For example,
our approach may elucidate which tumor-specific peptides
are presented to the immune system in a successful response
to a given cancer. Similarly, new and safer vaccines against
infectious diseases can be designed. For example, a peptide
vaccine that induces immunity to the variola virus (small-
pox) might allow universal immunization as opposed to the
limitations imposed by a live, albeit attenuated, whole virus
vaccine.
Our approach also has limitations. Given current tech-
nology, isolating and identifying HLA-derived class II pep-
tides is similar to searching for the proverbial needle in the
haystack. Peptides of lower abundance are less likely to be
identified than peptides of higher abundance. Class II pep-
tides are more difficult to identify than class I peptides, due
to the open ends of the peptide binding groove, allowing
both longer and more promiscuous peptides to be bound by
the HLA molecule. We are currently developing hybrid
Fourier-transform ion cyclotron resonance mass spectrom-
etry instrumentation to afford significantly higher peak ca-
pacity (resolving power) and the ability to detect peptides in
extremely low abundance. In the present study, we have
used a lymphocyte proliferation assay as a measure of recall
cellular immunity to “screen” and determine the immuno-
logic relevance of measles-derived peptides. However, the
generation of short-term and long-term measles peptide-
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specific T cell clones or cell lines and characterization of
HLA-DR3-restricted CD4 T cell epitopes of measles an-
tigens is very important for determining the functional spec-
ificity of the identified peptide. This is a topic for a separate
report.
In conclusion, we report the first class II measles-derived
peptide directly isolated from the class II HLA peptide
binding groove of the DR3 molecule in humans. A critical
contribution to this accomplishment was the development of
a comprehensive, integrated, and automated analytical strat-
egy that allowed for the identification of this peptide. Mass
spectrometry will be the cornerstone technology in directed
vaccine development by allowing the identification of nat-
urally processed pathogen-derived peptides for the rational
development of new peptide-based vaccines.
Materials and methods
Donor cell preparation
We generated an EBV-B cell line from peripheral blood
mononuclear cells (PBMC) of an HLA-DR3 homozygous
patient using 1  107 PBMC and the B95-8 strain of EBV
(American Type Culture Collection, Manassas, VA) in
RPMI medium containing 1 g/ml cyclosporin A (Neitzel,
1986). We obtained a heparinized venous blood (20 U/ml
heparin) sample from a single EBV-seronegative subject
(K.E., 16-year-old female, DRB1*0301, A*1/3, B*8/44,
C*7), who had been immunized with two doses of live-
attenuated measles vaccine (Attenuvax, Merck, West Point,
PA). The subject had no previous history of measles infec-
tion. The circulating MV-specific IgG antibody titer in the
subject’s sera was determined by and IgG whole virus
specific EIA (MeasleELISA, BioWhittaker, Walkersville,
MD). The subject was characterized as a measles vaccine
responder (EIA MV antibody titer  2.43 U/ml). B cells
were subcultured four to six times before being used as
antigen-presenting cells (APC) and were routinely moni-
tored for HLA-DR expression by flow cytometry.
Human subjects
Study participants included 95 healthy residents of Olm-
sted County, MN, aged 11 to 18 years. The subjects’ med-
ical records documented that each subject had been previ-
ously immunized with two doses of MMR-II vaccine
(Merck Research) containing the Edmonston strain of MV
(tissue culture infective dose, TCID50  1000) dose. All
subjects resided in a geographic area where no wild-type
MV had circulated in the community during the subjects’
lifetimes. The Institutional Review Board (IRB) of the
Mayo Clinic granted approval for the study, and peripheral
blood samples were drawn after informed consent was ob-
tained from each subject. Mononuclear leukocytes were
isolated by Ficoll–Hypaque (Amersham) density gradient
centrifugation.
Cell cultures and virus infection
We grew the Edmonston vaccine strain of measles in
Vero cells, in Dulbecco’s modified Eagle’s medium, sup-
plemented with 5% fetal calf serum (FCS) (virus stocks of
2.2  107 PFU/ml). Subsequently, EBV-B cells were in-
fected with live MV at a multiplicity of infection (m.o.i) of
1 PFU/cell for 1 h and maintained for 36–48 h at 37°C in
RPMI-1640 containing 2% FCS (Life Technologies, Gaith-
ersburg, MD). Equally sized batches of MV-infected and
uninfected cells were washed in PBS, pelleted, and stored
at-80°C. We monitored the infection of cells by flow cy-
tometry using purified monoclonal antibody (mAb) specific
for MV H protein tagged with FITC (Virostat, Portland,
ME) (Naniche et al., 1993) (data not shown).
Immunoaffinity purification of HLA-DR3 molecules and
associated peptides
An overview of our methodological strategy has been
previously published (Poland et al., 2001b). We used the
same number of uninfected and MV-infected cells for HLA-
DR-peptide complex purification. DR3-bound peptides
were isolated from immunoaffinity purified class II mole-
cules as previously described (Ovsyannikova et al., 2000;
Kirschmann et al., 1995). Briefly, 8 g cell pellets consisting
of either infected or uninfected cells were lysed in 1%
CHAPS, 150 mM NaCl, 20 mM Tris–HCl, pH 8.0, and 1
mM Pefabloc SC (Boehringer Mannheim GmbH, Ger-
many). The lysates were centrifuged at 100,000 g for 2 h
and the HLA-peptide complexes were immunoprecipitated
from the supernatants using an anti-HLA-DR mAb specific
for a HLA-DR monomorphic epitope (L227, IgG1) (Lamp-
son and Levy, 1980) covalently linked to CNBr-activated
Sepharose 4B beads (Sigma). The column was washed
sequentially with five separate washings, first using 10 col-
umn volumes of lysis buffer; five column volumes of 0.1%
deoxycholic acid (Boehringer Mannheim GmbH), 20 mM
Tris, pH 7.4; five column volumes of 20 mM Tris, 500 mM
NaCl, pH 7.4; five column volumes of 20 mM Tris, 150 mM
NaCl, pH 7.4, then using five column volumes of 20 mM
Tris, pH 7.4. After these series of wash steps, the HLA-DR-
peptide complexes were eluted from the affinity column (pH
11.5) with 0.1% deoxycholic acid and 50 mM glycine. We
neutralized the eluates with 2 M glycine and concentrated
them in a Centricon-10 (Amicon, Beverly, MA) before a
second round of precipitation by 14% acetic acid to disso-
ciate any bound peptides from DR3 molecules. HLA-DR3
molecules were more than 99% pure as assessed by SDS–
PAGE. We determined protein concentration by BCA assay
(Pierce, Rockford, IL). The peptides were concentrated in a
spin vacuum to 100 L aliquots (1  109 cells) and stored
at 	80°C for later analysis by MS.
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Peptide sequencing methodology
HLA class II restricted peptides were sequenced using
automated two dimensional liquid chromatography (strong
cation exchange followed by nanoscale reversed phase,
SCX, and nLC, respectively) coupled via nanoelectrospray,
to a Micromass Q-Tof-2 tandem mass spectrometer (Micro-
mass Ltd., Manchester, UK).
Prior to SCX, the peptide pool was desalted using a
reversed-phase microcolumn (Peptide Trap, Michrom
BioResources Inc., Auburn, CA). Desalted peptides, in SCX
mobile phase A, were loaded on a 300 m i.d. by 5-mm-
long column of Polysulfoethyl A (PolyLC, Inc., The Nest
Group, Southborough, MA). Peptides were step-eluted from
the SCX column using KCl concentrations of 20, 40, 60, 80,
100, 150, 200, 250, and 500 mM and were reconcentrated
on a precolumn before being chromatographed in the re-
versed-phase dimension. The precolumn was 300 m i.d.
by 5 mm long (LC Packings, San Francisco, CA) packed
with Magic C8 (5 m, 300 Å) (Michrom BioResources).
SCX mobile phase A was water/acetonitrile/n-propanol (95/
4/1 v/v/v), containing 10 mM potassium phosphate, pH 
3.1.
We performed nano scale LC in a 75 m i.d. PicoFrit
column (New Objective, Woburn, MA) packed with 5.5 cm
of Magic C18 (5 m, 200 Å) (Michrom BioResources Inc.).
Reverse mobile phase A was water/acetonitrile/ n-propanol
(98/1/1 v/v/v) with a 0.2% overall concentration of formic
acid. Reverse mobile phase B was acetonitrile/
n-propanol/water (80/10/10 v/v/v) containing 0.2% formic
acid overall. An LC pumping system, operated at 30 L/
min and split to 300 nL/min just prior to the switching
valve, was used to generate a mobile phase gradient from 0
to 50% through the reversed-phase nLC column after each
salt elution step.
We conducted tandem-MS experiments on precursor
ions from doubly, triply, or quadruply charged ions within
the m/z range of 450–1300; the collision energies were
automatically selected as a function of m/z and charge
(unless noted otherwise in the text) using argon as the
collision target. Tandem mass spectra were searched, using
SEQUEST software (ThermoFinnigan, San Jose, CA),
against the combined subset of human, bovine, and measles
proteins from the NR database (available February 2002
from ftp://ftp.ncbi.nih.gov/blast/db/nr) (Eng et al., 1994).
Synthetic peptides
Identified peptides were subsequently synthesized by the
Mayo Protein Core Facility (Rochester, MN) using N-(9-
fluorenyl)methoxycarbonyl protection chemistry and carbo-
diimide/N-hydroxybenzotriazole activation on a MPS 396
Multiple Peptide Synthesizer (Advanced Chemtech, Louis-
ville, KY). We purified each peptide by RP HPLC and
verified by mass spectrometry and amino acid (aa) analysis.
The following three peptides were used: (1) MV-derived
naturally processed 19 aa P1 peptide of the measles P
protein, ASDVETAEGGEIHELLRLQ; (2) MV-P2 peptide,
ASDVETAEGGEIHKLLRLQ;(3) MV-F control peptide of
the MV fusion protein, PLRHQATTASSTKP, randomly
chosen from MV F glycoprotein. Measles F control peptide
was chosen for this study because of the established impor-
tance of measles F protein in cell-mediated immune re-
sponse. In addition, Bakouche et al. show that the F protein
of MV is a potent T cell antigen (Bakouche et al., 1987).
The MV sequence corresponds to the Edmonston strain
(Parks et al., 2001).
T cell proliferation assay
We tested three measles-derived peptides (P1, P2, and F)
for the capacity to induce recall peptide-specific prolifera-
tive responses. PBMC (2  105) were incubated in medium
(RPMI-1640 supplemented with 5% autologous sera, peni-
cillin, 100 U/ml, 2-mercaptoethanol, and sodium pyruvate)
alone or in the presence of phytohemagglutinin (PHA, 5
g/ml) to assess cell vitality, or in the presence of measles-
synthetic peptides in a concentration of 20 g/ml, or live-
attenuated MV (50 PFU/well) (Attenuvax, Merck). Cultures
were incubated in a total volume of 200 l for 3 days (37°C,
5% CO2) and pulsed during the last 18 h with tritiated
thymidine 3H (1 Ci/well). We then harvested cells onto
glass fiber filters, using a 96-well harvesting system (Ska-
tron Instruments, Norway). The amount of incorporated
radioactivity was determined by a liquid scintillation
counter (Packard Instrument Co., Boston, MA) and the
results were expressed as SIs. We calculated the SI as the
ratio of mean cpm of triplicate wells of peptide stimulated to
mean cpm of unstimulated control wells. Stimulation indi-
ces of3 were considered to represent significant responses
(Bautista-Lo´pez et al., 2000; Marttila et al., 1999). We used
six replicates of cpm values for unstimulated cells; three
replicates each were used for T cells stimulated with MV-
P1, MV-P2, MV-F, and live-attenuated MV vaccine. For
each subject, median cpm was calculated for unstimulated
cells, as well as for cells stimulated with MV-P1, MV-P2,
and MV. These median values are used in all subsequent
comparisons. Stimulation indices were calculated for P1,
P2, F peptides, and MV using the median of the six un-
stimulated cpm values as the denominator.
Statistical analysis
For descriptive analyses, we used medians and ranges for
continuous variables and frequencies for categorical vari-
ables. We compared cpm for MV-stimulated, MV-P1-stim-
ulated and MV-P2-stimulated cells with unstimulated cells
using Wilcoxon signed rank tests. Associations between the
continuously distributed stimulation indices for MV-P1,
MV-P2 peptides, and MV were determined using Spearman
rank correlation coefficients. Stimulation indices were sub-
sequently dichotomized into positive or negative using a cut
504 I.G. Ovsyannikova et al. / Virology 312 (2003) 495–506
point of 3.0. We then compared MV positivity with MV-P1
and MV-P2 positivity using estimates of sensitivity.
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